AFT PHARMACEUTICALS

AFT
End-of-day quote. End-of-day quote  - 04/16
4.1NZD -1.68%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: March 2020 2021
Net sales1 106110
EBITDA1 12,511,0
Operating profit (EBIT)1 11,410,00
Operating Margin 10,8%9,07%
Pre-Tax Profit (EBT)1 12,98,62
Net income1 12,77,79
Net margin 12,0%7,07%
EPS2 0,120,07
Dividend per Share2 --
Last update 05/19/202004/07/2021
1 NZD in Million
2 NZD
Estimates
Finances - Leverage
Fiscal Period: March 2020 2021
Net Debt1 41,131,8
Net Cash position1 --
Leverage (Debt / EBITDA) 3,28x2,89x
Free Cash Flow1 -0,60
ROE (Net Profit / Equities) 114%19,6%
Shareholders' equity1 11,239,7
ROA (Net Profit / Asset) -12,8%
Assets1 -60,8
Book Value Per Share2 0,180,33
Cash Flow per Share2 -0,07
Capex1 6,565,28
Capex / Sales 6,21%4,78%
Last update 05/19/202004/07/2021
1 NZD in Million
2 NZD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 429 M NZD -
Entreprise Value (EV) 461 M NZD 454 M NZD
Valuation 2021e 2022e
P/E ratio (Price / EPS) 55,1x 27,9x
Capitalization / Revenue 3,89x 3,27x
EV / Revenue 4,18x 3,52x
EV / EBITDA 41,8x 20,6x
Yield (DPS / Price) - 0,56%
Price to book (Price / BVPS) 12,5x 9,23x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 9,07% 15,7%
Operating Leverage (Delta EBIT / Delta Sales) - 5,64x
Net Margin (Net Profit / Revenue) 7,07% 11,7%
ROA (Net Profit / Asset) 12,8% 22,9%
ROE (Net Profit / Equities) 19,6% 29,4%
Rate of Dividend - 15,5%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,78% 4,12%
Cash Flow / Sales 6,40% 12,6%
Capital Intensity (Assets / Sales) 0,55x 0,51x
Financial Leverage (Net Debt / EBITDA) 2,89x 1,12x
Price Earning Ratio
EPS & Dividend